Johnson & Johnson Falls After Earnings, Vaccine Candidate Trial Pause

The equity is up over 14% year-over-year

Deputy Editor
Oct 13, 2020 at 11:09 AM
facebook twitter linkedin


Johnson & Johnson (NYSE:JNJ) is making waves this morning, after the company reported third-quarter earnings and revenue that topped Wall Street's estimates. Johnson & Johnson cited a faster-than-expected rebound in procedures utilizing its medical devices was a large factor in its quarterly beat, as well as a strong demand for its cancer drugs. However, separately, the company was forced to pause a clinical trial of its coronavirus vaccine candidate after a participant in the study came down with an unexplained illness. Johnson & Johnson stock is now down 1.7%, last seen trading at $149.24 this morning.

On the charts, JNJ is continuing its trend of trading sideways, plateauing after its late-April recovery and all-time high of $157. In fact, today's slip sent the equity back below $150 after spending the last two session above that territory. The 30-day moving average could provide some support moving forward, after acting as a rejection area in September, and for the year, JNJ boasts a 14.4% lead. 

Meanwhile, in the options pits, calls have been quite popular. In fact, JNJ sports a 50-day call/put volume ratio of 3.45 at the International Securities Exchange (ISE), Cboe Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), which sits in the 82nd percentile of its annual range. Should this bullish sentiment begin to unwind, it could send the security lower.

Today's options pits are singing a slightly different tune. While over 14,000 calls have crossed the tape so far today, 10,000 puts have also exchanged hands -- eight times the intraday average and volume pacing in the 99th percentile of the last 12 months. Most popular by far is the October 155 call, followed by the 145 put from the same series. 

Now seems like a good time to weigh in on JNJ options, Johnson & Johnson stock's Schaeffer's Volatility Index (SVI) of 23% sits in just the 17th percentile of all other annual readings, meaning the equity sports attractively priced premiums at the moment.

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners